

Supplementary Table 2. Baseline characteristics of the study population stratified by non-NAFLD (defined by HSI), liver steatosis, and advanced liver fibrosis

Characteristic	NAFLD (-) (n=1,696)	Hepatic steatosis alone (n=1,413)	Advanced liver fibrosis (n=79)	P value
Age, yr	57.7±10.0	55.0±10.0 ^a	65.7±6.6 ^{a,b}	0.003 ^c
Male sex	785 (46.3)	754 (53.4) ^a	52 (65.8) ^{a,b}	<0.001 ^c
Duration of diabetes, yr	8.1±7.2	6.4±6.2 ^a	8.1±6.6 ^b	<0.001 ^c
BMI, kg/m ²	22.7±2.2	26.3±2.7 ^a	29.1±2.8 ^{a,b}	<0.001 ^c
WC, cm	79.8±7.5	87.8±7.5 ^a	92.3±6.9 ^{a,b}	<0.001 ^c
SBP, mm Hg	132.6±17.8	136.6±17.4 ^a	142.2±16.6 ^{a,b}	<0.001 ^c
DBP, mm Hg	84.1±10.9	94.6±279.6 ^a	86.3±11.2	0.179
FPG, mg/dL	158.1±59.2	162.6±56.9 ^a	151.0±56.7	0.186
HbA1c, %	8.3±2.1	8.4±1.8 ^a	8.0±1.4 ^b	0.970
KITT, %/min	2.2±1.0	1.9±0.9 ^a	1.7±0.7 ^a	<0.001 ^c
Total cholesterol, mg/dL	192.3±39.1	200.4±41.6 ^a	193.3±36.3	<0.001 ^c
Triglyceride, mg/dL	127.4±80.3	170.6±137.3 ^a	147.6±62.1 ^{a,b}	<0.001 ^c
HDL-C, mg/dL	53.2±14.4	49.1±12.5 ^a	49.3±12.1 ^a	<0.001 ^c
LDL-C, mg/dL	113.8±34.0	118.9±36.9 ^a	114.8±31.6	0.001 ^c
AST, IU/L	26.9±13.4	29.2±17.5 ^a	32.2±15.8 ^a	<0.001 ^c
ALT, IU/L	23.4±13.8	38.6±33.0 ^a	29.7±14.9 ^{a,b}	<0.001 ^c
eGFR, mL/min/1.73 m ²	91.0±15.5	91.9±15.5	85.6±14.8 ^{a,b}	0.986
Hs-CRP, mg/dL	0.6 (0.3–1.3)	0.9 (0.5–1.9) ^a	1.0 (0.5–2.1) ^a	<0.001 ^c
Hypertension	421 (24.8)	438 (31.0) ^a	26 (32.9)	<0.001 ^c
Insulin	192 (11.3)	143 (10.1)	13 (16.5)	0.157
Metformin	668 (39.4)	689 (48.8) ^a	25 (31.6) ^b	<0.001 ^c
Sulfonylurea	878 (51.8)	742 (52.5)	45 (57.0)	0.638
Thiazolidinedione	167 (9.8)	114 (8.1)	14 (17.7) ^{a,b}	0.007 ^c
ARB/ACE inhibitors	76 (4.5)	91 (6.4) ^a	9 (11.4) ^a	0.004 ^c
Statin	234 (13.8)	267 (18.9) ^a	4 (5.1) ^{a,b}	<0.001 ^c
Incident CKD	255 (15.0)	198 (14.0)	26 (32.9) ^{a,b}	<0.001 ^c

Values are presented as mean ± standard deviation, number (%), or median (interquartile range).

NAFLD, nonalcoholic fatty liver disease; HSI, hepatic steatosis index; BMI, body mass index; WC, waist circumference; SBP, systolic blood pressure; DBP, diastolic blood pressure; FPG, fasting plasma glucose; HbA1c, glycosylated hemoglobin; KITT, rate constant for plasma glucose disappearance; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; AST, aspartate aminotransferase; ALT, alanine aminotransferase; eGFR, estimated glomerular filtration rate; Hs-CRP, high-sensitivity C-reactive protein; ARB, angiotensin II receptor blockers; ACE, angiotensin converting enzyme; CKD, chronic kidney disease.

^aIndicates $P < 0.05$ compared with NAFLD (-), ^bIndicates $P < 0.05$ compared with hepatic steatosis without advanced liver fibrosis, ^cStatistically significant.